This disparity is a call for action for the communities to not only focus on implementing scientific advances, but also consider how we could act together to bring clinical advances to cancer patients at large, in particular situations such as EGFR mutations, where the prevalence in lung adenocarcinoma is 50% or higher. This evidence concerns the gene EGFR and lung adenocarcinoma.